In a larger analysis performed on residual tumours from patients previously included in the GeparTrio study (n = 1,151), of whom 58% had no pCR (n = 667) and 5.4% (n = 36) were HR-negative, Ki-67 >35% was associated with 1.73-fold increase in the risk of recurrence (95% CI 0.87–3.42) in HR-negative tumours versus Ki-67 ≤35% (64). This evidence concerns the gene MKI67 and neoplasm.